Entrada Therapeutics Boeing Bond
| TRDA Stock | USD 18.80 0.75 4.16% |
Entrada Therapeutics holds a debt-to-equity ratio of 0.116. At present, Entrada Therapeutics' Net Debt is projected to decrease significantly based on the last few years of reporting. The current year's Debt To Equity is expected to grow to 0.04, whereas Short and Long Term Debt Total is forecasted to decline to about 51.8 M. With a high degree of financial leverage come high-interest payments, which usually reduce Entrada Therapeutics' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Entrada Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Entrada Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Entrada Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Entrada Therapeutics' stakeholders.
For most companies, including Entrada Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Entrada Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Entrada Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 1.6653 | Book Value 11.933 | Operating Margin (1.11) | Profit Margin 0.2553 | Return On Assets 0.0695 |
Entrada |
Given the importance of Entrada Therapeutics' capital structure, the first step in the capital decision process is for the management of Entrada Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Entrada Therapeutics to issue bonds at a reasonable cost.
| Popular Name | Entrada Therapeutics Boeing Co 2196 |
| Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
| Equity ISIN Code | US29384C1080 |
| Bond Issue ISIN Code | US097023DG73 |
Entrada Therapeutics Outstanding Bond Obligations
| Boeing Co 2196 | US097023DG73 | Details | |
| HSBC Holdings PLC | US404280DR76 | Details | |
| MGM Resorts International | US552953CD18 | Details | |
| AerCap Global Aviation | US00773HAA59 | Details |
Understaning Entrada Therapeutics Use of Financial Leverage
Entrada Therapeutics' financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Entrada Therapeutics' total debt position, including all outstanding debt obligations, and compares it with Entrada Therapeutics' equity. Financial leverage can amplify the potential profits to Entrada Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Entrada Therapeutics is unable to cover its debt costs.
| Last Reported | Projected for Next Year | ||
| Net Debt | 628 K | 659.4 K | |
| Short and Long Term Debt Total | 68.2 M | 51.8 M | |
| Short Term Debt | 15.8 M | 13.1 M | |
| Net Debt To EBITDA | (1.96) | (1.86) | |
| Debt To Equity | 0.03 | 0.04 | |
| Interest Debt Per Share | 0.24 | 0.33 | |
| Debt To Assets | 0.02 | 0.03 | |
| Total Debt To Capitalization | 0.03 | 0.04 | |
| Debt Equity Ratio | 0.03 | 0.04 | |
| Debt Ratio | 0.02 | 0.03 | |
| Cash Flow To Debt Ratio | 17.68 | 18.56 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:Check out the analysis of Entrada Therapeutics Fundamentals Over Time. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.